Valneva SE INRLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INRLF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.90
- Day Range
- $3.78–3.78
- 52-Week Range
- $3.35–8.55
- Bid/Ask
- $3.67 / $3.90
- Market Cap
- $526.00 Mil
- Volume/Avg
- 2,700 / 1,747
Key Statistics
- Price/Earnings (Normalized)
- 18.33
- Price/Sales
- 3.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.05%
Company Profile
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 676
- Website
- https://www.valneva.com
Comparables
Valuation
|
Metric
|
INRLF
|
002007
|
CVAC
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.33 | 26.38 | 12.03 |
Price/Book Value | 4.57 | 3.07 | 0.81 |
Price/Sales | 3.15 | 6.50 | 10.75 |
Price/Cash Flow | — | 17.87 | — |
Price/Earnings
INRLF
002007
CVAC
Financial Strength
|
Metric
|
INRLF
|
002007
|
CVAC
|
|---|---|---|---|
Quick Ratio | 1.06 | — | 3.25 |
Current Ratio | 1.65 | — | 3.56 |
Interest Coverage | −3.28 | — | −41.31 |
Quick Ratio
INRLF
002007
CVAC
Profitability
|
Metric
|
INRLF
|
002007
|
CVAC
|
|---|---|---|---|
Return on Assets (Normalized) | −17.87% | — | −28.58% |
Return on Equity (Normalized) | −56.89% | — | −41.05% |
Return on Invested Capital (Normalized) | −23.08% | — | −39.11% |
Return on Assets
INRLF
002007
CVAC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xjyckqbfh | Dzdlt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wqrlmksv | Hynfpk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bcxrmlhy | Plfmcnw | $97.8 Bil | |
MRNA
| Moderna Inc | Jdrpbclp | Tskhj | $38.8 Bil | |
ARGX
| argenx SE ADR | Jzvwvbyy | Fsfq | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kpxsdlv | Kllz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Prrgjcrzd | Cbhljd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lvbxpnyl | Gskzn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zxhkxpfc | Tbgxyx | $12.5 Bil | |
INCY
| Incyte Corp | Bhhbvgcn | Mqvqcx | $11.5 Bil |